At the news
? NEUTRALIMPACT 5/10 PRESS-RELEASE filed Mar 2, 2026 at 06:10 ET
Royalty Pharma is providing $250 million in non-dilutive, royalty-backed financing to Zymeworks, securing 30% of global tiered royalties from Ziihera® (zanidatamab) sales until repayment is complete. Zymeworks retains 70% of royalties and full rights post-repayment, using the capital for share repurchases, strategic acquisitions, and extending its cash runway beyond 2028.
- Royalty Pharma is funding $250 million to Zymeworks via a non-recourse royalty-backed note.
- Repayment will come from 30% of worldwide tiered royalties on Ziihera sales; Royalty Pharma receives up to 1.65x–1.925x the note amount depending on timing.
- Zymeworks retains 70% of royalties during repayment and full rights thereafter.
- Proceeds will support Zymeworks' stock buybacks, potential acquisitions, and cash runway beyond 2028.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access